JMAR Successfully Completes Water-Monitoring Test Program for the City of Anaheim; Test Program Validates BioSentry's Value to the Homeland Security Market.

SAN DIEGO -- JMAR Technologies, Inc. (NASDAQ: JMAR), a leading developer of advanced laser technology, has successfully completed its 60-day water-monitoring test program with the City of Anaheim. The test program was instituted to demonstrate the value of the BioSentry(TM) System as part of the City's Homeland Security Initiative. In the final report presented to Anaheim last week, BioSentry not only met but exceeded expectations.

The BioSentry System was installed in Anaheim's City Hall West for the purpose of testing BioSentry's ability to detect the presence of Cryptosporidium and other unknown pathogens in a water distribution system. Cryptosporidium is one of the major pathogens identified by the EPA/Department of Homeland Security (DHS) as a target contaminant which, if introduced into a water supply, could cause severe facility disruption and possible fatalities. The BioSentry successfully passed the test protocol agreed upon by JMAR and the City of Anaheim, establishing its capability to detect contaminants at levels that were actually far below the concentration levels indicative of a deliberate contamination event.

"We are delighted to have the opportunity to work with the City of Anaheim to test BioSentry in such an important National Security initiative," said Dr. Neil Beer, JMAR's president and CEO. "Anaheim is one of the more proactive cities in America when it comes to homeland security and water quality, and we are certainly pleased that the BioSentry exceeded our expectations."

BioSentry(TM) is a contamination warning system for waterborne microorganisms. Whereas current water monitoring depends on batch sampling of water and time-consuming lab analysis, BioSentry(TM) uses laser-based technology to provide continuous, on-line, real-time monitoring for harmful bacteria and protozoa. BioSentry(TM) is targeted toward a number of applications across multiple industries, including homeland security, the beverage industry, and municipal drinking water utilities.

About Anaheim

Founded in 1857, the City of Anaheim is one of the nation's premier municipalities and California's 10th most populous city. As the oldest city in Orange County, Anaheim covers 50 square miles, with more than 345,000 residents and 2,077 employees. Anaheim operates the only municipal water and electric utility in Orange County. The municipal corporation's annual budget is $1.298 billion. The city boasts world-class organizations such as the Anaheim Angels, Boeing, CKE Restaurants, Inc., L-3 Communications, the Mighty Ducks of Anaheim, Pacific Sunwear, The Walt Disney Company and the USA Men's Vollyball team. Annually, Anaheim also welcomes millions of visitors to the city, truly making it where the world comes to live, work and play. For more information, please visit www.anaheim.net.

About JMAR

JMAR Technologies, Inc. is a leading innovator in the development of laser-based equipment for imaging, analysis and fabrication at the nano-scale. The Company is leveraging more than a decade of laser and photonics research to develop a diverse portfolio of products with commercial applications in rapidly growing industries, while continuing to carry out research and development for the U.S. Government. JMAR is targeting the nanotechnology, bioscience and semiconductor industries with its BriteLight(TM) Laser; X-ray Light Source; Compact X-ray Microscope -- for 3D visualization of single cells and polymers; and X-ray Nano Probe -- enabling interaction, analysis and materials modification at the nano-scale. JMAR also develops, manufactures and markets its BioSentry(TM) microorganism early-warning system and maintains a strategic alliance for the production of the READ chemical sensor for the homeland security, environmental and utility infrastructure industries.

This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. Actual results could differ materially from these forward-looking statements as a result of a number of factors, including the risk that the performance validation tests of the BioSentry Beta units are not successfully completed due to unforeseen issues with the installation and operation of the units outside of the controlled environment of JMAR's facility, delays in completion of the X-ray Microscope and X-ray Nano Probe prototypes and transition to production units, the failure of the technology to perform as predicted, competition from alternative technologies, uncertainties as to the size of the markets , cost and margins for JMAR's products, failure to obtain market acceptance, current or future government regulations affecting the use of JMAR's products, the lack of availability of critical components, the degree of protection from future patents, other risks associated with the development or acquisition of new products or technologies and those risks detailed in the Company's Form 10-K for the year ended December 31, 2005 filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. JMAR Technologies, Inc. does not assume any duty to publicly update or revise the material contained herein.